Company Focus
Icon
Latest Icon News
Biotechnology
Irish contract research organization ICON has retained its position as the most active CRO worldwide in the first quarter of 2025, according to a new analysis by GlobalData. 16 May 2025
Related News
Insights
Company Spotlight
Neurocrine develops and discovers treatments for neurological and endocrine-related diseases and disorders.
Latest News & Features of interest to Icon
Pharmaceutical
Danish diabetes and weight loss juggernaut Novo Nordisk is to part ways with its chief executive Lars Fruergaard Jørgensen as the group seeks to reverse its fortunes. 16 May 2025
Pharmaceutical
Chinese pharmaceutical group Jiangsu Hengrui Pharmaceuticals is set to raise up to HK$9.89 billion ($1.27 billion) through a public offering on the Hong Kong Stock Exchange, marking one of the largest listings in the city this year. The move signals renewed momentum in Hong Kong’s capital markets after a prolonged slump. 16 May 2025
Pharmaceutical
US biopharma Biohaven has been told by the US Food and Drug Administration (FDA) that the agency is extending the PDUFA date for the company’s troriluzole new drug application (NDA) for the treatment of spinocerebellar ataxia (SCA) by three months. 16 May 2025
Biotechnology
The US Food and Drug Administration (FDA) has approved Incyte’s Zynyz (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). 16 May 2025
Biotechnology
The Institute for Clinical and Economic Review (ICER) has released a Final Evidence Report assessing the comparative clinical effectiveness and value of sonpiretigene isteparvovec for the treatment of advanced retinitis pigmentosa. 16 May 2025
Pharmaceutical
Chinese AI drug developer METiS Pharmaceuticals is preparing for a Hong Kong initial public offering that could raise up to $200 million, highlighting the ongoing surge of investment in artificial intelligence-powered drug discovery - even as many companies in the sector remain unprofitable. 16 May 2025
Biotechnology
Irish contract research organization ICON has retained its position as the most active CRO worldwide in the first quarter of 2025, according to a new analysis by GlobalData. 16 May 2025
Pharmaceutical
Neurocrine Biosciences , the American biotech, has unveiled new data showing its drug Crenessity (crinecerfont) may help children and adults with classic congenital adrenal hyperplasia (CAH) achieve better hormone balance and reduce steroid use. The findings were presented at the 2025 American Association of Clinical Endocrinology Annual Meeting in Orlando. 16 May 2025
Biotechnology
Pathos AI, a US biotech specializing in artificial intelligence for cancer drug development, has raised $365 million in a series D financing round, lifting its valuation to about $1.6 billion. The company, based in Boston, plans to use the funds to advance its clinical-stage pipeline and further develop its proprietary AI foundation model for oncology. 16 May 2025
Biotechnology
US clinical-stage biotech Therini Bio yesterday revealed that it raised $39 million in a Series A extension financing, which increased the company’s Series A total to $75 million. 16 May 2025
Latest In Brief for Icon
Biotechnology
The Indian subsidiary of UK pharma major AstraZeneca has announced a Central Drugs Standard Control Organization (CDSCO) approval to import for sale and distribution of trastuzumab deruxtecan concentrate for solution for infusion 100mg for an additional indication, according to a Healthcare Radius report. 12 May 2025
Latest Relevant Ones To Watch News
California’s BioMarin Pharmaceutical is to acquire Inozyme Pharma or $4 per share in an all-cash transaction for a total consideration of approximately $270 million. 16 May 2025
30 April 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze